Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Lymphoma 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × CX 3543 × Clear all
NCT00780663 2011-06-15

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Cylene Pharmaceuticals

Phase 2 Completed
25 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT00955786 2009-08-10

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Cylene Pharmaceuticals

Phase 1 Completed
48 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡